Vol. 3 No. 5 (2023)
Reimbursement Recommendations

Palovarotene (Sohonos)

Published May 30, 2023

Key Messages

  • CADTH recommends that Sohonos be reimbursed by public drug plans to reduce the formation of heterotopic ossification (HO) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP), if certain conditions are met.
  • Sohonos should only be covered to treat patients who have a clinical diagnosis of FOP and the R206H ACVR1 mutation as confirmed by genetic testing, and who do not have completely fused joints over the whole body.
  • Sohonos should only be reimbursed if prescribed by an expert in the diagnosis and management of FOP and if the cost of Sohonos is reduced. While receiving Sohonos, patients (and their caregivers, for pediatric patients) and their physicians should have ongoing and regular discussions to assess the benefits and risks of treatment with Sohonos.